AI assistant
Armata Pharmaceuticals, Inc. — Director's Dealing 2014
Feb 24, 2014
34152_dirs_2014-02-24_12290f5e-bee3-48a3-bbaa-7ceef38aaaca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: AmpliPhi Biosciences Corp (APHB)
CIK: 0000921114
Period of Report: 2014-02-18
Reporting Person: WILLIAMS GWYNN (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series B Convertible Preferred Stock | $ | Common Stock (32250610) | Indirect | ||
| Warrant (right to buy) | $0.14 | 2018-02-04 | Common Stock (4351816) | Indirect | |
| Warrant (right to buy) | $0.14 | 2018-03-04 | Common Stock (892857) | Indirect | |
| Warrant (right to buy) | $0.14 | 2018-04-12 | Common Stock (892857) | Indirect | |
| Warrant (right to buy) | $0.14 | 2018-05-13 | Common Stock (892857) | Indirect | |
| Warrant (right to buy) | $0.14 | 2018-06-26 | Common Stock (8062652) | Indirect |
Footnotes
F1: The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.
F2: Pursuant to its terms, each share of Series B Convertible Preferred Stock is convertible into ten (10) shares of Common Stock.
F3: Gwynn Williams controls Pendinas Limited. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Act of 1934, as amended) by Mr. Williams. Mr. Williams disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.